

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY AND APPLICATION FOR CHANGES IN THE INDUSTRIAL AND COMMERCIAL REGISTRATION

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the announcement dated 4 September 2026 made by the Company in relation to the resolutions passed at the 8th Board meeting of the Company for the financial year ending 31 December 2026, and in particular to the resolution relating to the proposed amendments to the Articles of Association of the Company (the “**2026 2nd Proposed AOA Amendments**”) and the application for changes in the industrial and commercial registration.

Having regard to the Company’s actual circumstances and business development needs, the Company proposes to adjust its business scope by adding the following business activities: (i) marketing planning; (ii) market research (excluding foreign-related surveys); (iii) technical services, technology development, technical consultancy, technology exchange, technology transfer and technology promotion; (iv) software development; (v) data processing and storage support services; and (vi) information system operation and maintenance services (the “**Proposed Adjustment to Business Scope**”).

In light of the Proposed Adjustment to Business Scope and the need to standardise the descriptions of the Company’s existing business scope in accordance with the Catalogue of Standardised Expressions for Business Scope (《经营范围规范表述目录》) (the “**Business Scope Catalogue**”) issued by the State Administration for Market Regulation (国家市场监督管理总局) and in force as at the date of this announcement, and pursuant to applicable laws, regulations and regulatory documents, including the Company Law of the People’s Republic of China (《中华人民共和国公司法》) (the “**PRC Company Law**”), the Guidelines for Articles of Association of Listed Companies (《上市公司章程指引》) issued by the China Securities Regulatory Commission (中国证券监督管理委员会) (as revised in March 2025) and the Business Scope Catalogue, the Company proposes to amend its Articles of Association accordingly.

The proposed amendments to the existing Articles of Association are set out below (with insertions in bold and underline, and deletions in bold strikethrough):

Before the 2026 2 nd Proposed AOA Amendments	After the 2026 2 nd Proposed AOA Amendments
Article 12 The business scope of the Company shall be subject to the items as approved by the competent company registration authority.	Article 12 The business scope of the Company shall be subject to the items as approved by the competent company registration authority.
The business scope of the Company includes:	The business scope of the Company includes:

Before the 2026 2 nd Proposed AOA Amendments	After the 2026 2 nd Proposed AOA Amendments
production of Chinese traditional herbal medicine, Chinese traditional medicine, herbal pieces, western pharmaceutical preparation and chemical medicinal feedstock; processing, manufacturing, wholesale and retail of chemical preparation, new herbal medicinal products, medical apparatus and instruments, nutritional supplement and chemical reagents; processing and other logistics in relation to traditional Chinese medicinal products; purchases and sales through agents, and wholesale and retail of hygienic products, exercise machines, disinfection supplies for daily life and environment hygiene, skin protection medical products, general merchandise, clothes, shoes and hats, and home appliances; storage, advertising, technology development and transfer, economic information consultation service, house renting; purchases and sales through agents, and wholesale and retail of computers, software and analytical instruments; retail of family planning supplies; renting of medical equipment; exports of self-produced products and technologies; imports of feedstock, supplementary raw material, apparatus and instruments, machinery equipment, spare parts and corresponding technologies for the production of the Company (except commodities and technologies which are prohibited to be imported or exported by the PRC government or the sale and/or operation of which are limited to state-owned enterprises); business of processing with imported materials and forms of OEM and compensation trades; purchases of Chinese traditional medicines. Business items to be conducted/operated by branches/divisions/subsidiaries of the Company: medical packaging material, veterinary, bait additives, feed, bait, production of drugs for livestock, production of feed additives, livestock breeding, fresh water animal breeding and planting, catering, conference services; retail of standard packaged food, edible oil, non-staple food, flavor; purified water and hygienic products; standard packaged drinking water; production and sales of bottle water; beverage; powder drinks, production and sales of tea drinks; operation limited only to branches: sales of antibiotics and bio-medicines and chemical	<u>Licensed items: pharmaceutical manufacturing; contract manufacturing of pharmaceuticals; wholesale of pharmaceuticals; retail of pharmaceuticals; import and export of pharmaceuticals; operation of Class III medical devices; decoction services for prepared Chinese medicinal slices; internet information services; internet information services relating to pharmaceuticals; internet information services relating to medical devices; Class II value-added telecommunications services; food production; food sales; production of health food; production of disinfectants (excluding hazardous chemicals); road freight transportation (excluding dangerous goods); and printing of packaging and decorative printed matter. (For business activities that are subject to approval under applicable laws and regulations, such activities shall be carried out only upon obtaining approval from the relevant authorities. The specific business items shall be subject to the relevant approval documents or licences issued by the relevant authorities.)</u> <u>General items: marketing planning; market research (excluding foreign-related surveys); technical services, technology development, technical consultancy, technology exchange, technology transfer and technology promotion; software development; data processing and storage support services; information system operation and maintenance services; sale of Class I medical devices; sale of Class II medical devices; sale of sanitary products and disposable medical products; sale of personal hygiene products; sale of disinfectants (excluding hazardous chemicals); sale of pre-packaged health food; wholesale of cosmetics; retail of cosmetics; sale of daily general merchandise; wholesale of clothing and apparel; retail of clothing and apparel; wholesale of footwear and headwear; retail of footwear and headwear; sale of household electrical appliances; sale of daily sundry goods; sale of daily</u>

Before the 2026 2 nd Proposed AOA Amendments	After the 2026 2 nd Proposed AOA Amendments
medicines; The following business items may only be conducted/operated by branches/divisions/subsidiaries of the Company: medical diagnoses and treatment; medical tests, traditional Chinese medicine department, internal medicine, paediatrics, dermatology, Chinese Acupuncture, biological medicines, diagnostic medicine, sales of the second class psychoactive drugs; packaging and printing; road transportation; purchases and sales through agents, wholesale and retail of wines and alcohol, sugar, tea, beverage and bee products; narcotic drug (only limited to pericarpium papaveris); toxic drugs for medical use; protein assimilation agent; wholesale of peptide hormone; the sales of food, pre-packaged food, unpacked food; research, development and sales of biological engineering and biological products, chemical products (except for dangerous goods); wholesale of health food (tablets, hard gelatine capsules, teabag, oral use); wholesale and retail of edible agricultural products (as licensed); and scientific research and technical services (If the government has formulated monopoly operation over any of the abovementioned business items, the company Business operation mode: processing and manufacturing, import and export, wholesale and retail services.	<u>necessities; sale of chemical products (excluding chemical products subject to licensing requirements); sale of specialty chemical products (excluding hazardous chemicals); manufacture of specialty chemical products (excluding hazardous chemicals); manufacture of basic chemical raw materials (excluding the manufacture of hazardous chemicals and other chemical products subject to licensing requirements); wholesale of edible agricultural products; retail of edible agricultural products; cultivation of Chinese medicinal herbs; purchase of Chinese medicinal herbs; purchase and sale of locally produced Chinese medicinal herbs (excluding prepared Chinese medicinal slices); leasing of non-residential real estate; housing leasing; leasing of machinery and equipment; warehousing equipment leasing services; office equipment leasing services; wholesale of computer software, hardware and ancillary equipment; retail of computer software, hardware and ancillary equipment; sale of instruments and meters; import and export of goods; import and export of technology; import and export agency services; import and export of food; primary processing of edible agricultural products; wholesale of protective equipment for medical personnel; retail of protective equipment for medical personnel; manufacture of daily-use masks (non-medical); sale of daily-use masks (non-medical); manufacture of pharmaceutical production equipment; sale of pharmaceutical production equipment; sale of drug testing instruments; sale of specialised packaging equipment; packaging services; general cargo warehousing services (excluding hazardous chemicals and other items subject to licensing or approval requirements); loading, unloading and handling; domestic freight forwarding agency services; road freight transportation by general freight vehicles with a gross vehicle weight of 4.5 tonnes or less (excluding online freight transportation and dangerous goods); manufacture of bio-based materials; sale of bio-based materials; research and</u>

Before the 2026 2 nd Proposed AOA Amendments	After the 2026 2 nd Proposed AOA Amendments
	<u>development of bio-based material technology; research and development of new material technology; research, development and application of cell technology; medical research and experimental development (excluding the development and application of human stem cell technology and genetic diagnosis and treatment technology); manufacture of eco-environmental materials; sale of eco-environmental materials; sale of recycled resources; tree planting and cultivation business; and leasing of land use rights. (Except for items that are subject to approval in accordance with applicable laws and regulations, the Company may independently carry out the foregoing general business activities in accordance with law on the basis of its business licence.)</u> The business scope of the Company includes: production of Chinese traditional herbal medicine, Chinese traditional medicine, herbal pieces, western pharmaceutical preparation and chemical medicinal feedstock; processing, manufacturing, wholesale and retail of chemical preparation, new herbal medicinal products, medical apparatus and instruments, nutritional supplement and chemical reagents; processing and other logistics in relation to traditional Chinese medicinal products; purchases and sales through agents, and wholesale and retail of hygienic products, exercise machines, disinfection supplies for daily life and environment hygiene, skin protection medical products, general merchandise, clothes, shoes and hats, and home appliances; storage, advertising, technology development and transfer, economic information consultation service, house renting; purchases and sales through agents, and wholesale and retail of computers, software and analytical instruments; retail of family planning supplies; renting of medical equipment; exports of self-produced products and technologies; imports of feedstock, supplementary raw material,

Before the 2026 2 nd Proposed AOA Amendments	After the 2026 2 nd Proposed AOA Amendments
	apparatus and instruments, machinery equipment, spare parts and corresponding technologies for the production of the Company (except commodities and technologies which are prohibited to be imported or exported by the PRC government or the sale and/or operation of which are limited to state-owned enterprises); business of processing with imported materials and forms of OEM and compensation trades; purchases of Chinese traditional medicines. Business items to be conducted/operated by branches/divisions/subsidiaries of the Company: medical packaging material, veterinary, bait additives, feed, bait, production of drugs for livestock, production of feed additives, livestock breeding, fresh water animal breeding and planting, catering, conference services; retail of standard packaged food, edible oil, non-staple food, flavor; purified water and hygienic products; standard packaged drinking water; production and sales of bottle water; beverage; powder drinks, production and sales of tea drinks; operation limited only to branches: sales of antibiotics and bio-medicines and chemical medicines; The following business items may only be conducted/operated by branches/divisions/subsidiaries of the Company: medical diagnoses and treatment; medical tests, traditional Chinese medicine department, internal medicine, paediatrics, dermatology, Chinese Acupuncture, biological medicines, diagnostic medicine, sales of the second class psychoactive drugs; packaging and printing; road transportation; purchases and sales through agents, wholesale and retail of wines and alcohol, sugar, tea, beverage and bee products; narcotic drug (only limited to pericarpium papaveris); toxic drugs for medical use; protein assimilation agent; wholesale of peptide hormone; the sales of food, pre-packaged food, unpacked food; research, development and sales of biological engineering and biological products, chemical products (except for dangerous goods); wholesale of health food

Before the 2026 2 nd Proposed AOA Amendments	After the 2026 2 nd Proposed AOA Amendments
	(tablets, hard gelatine capsules, teabag, oral use); wholesale and retail of edible agricultural products (as licensed); and scientific research and technical services (If the government has formulated monopoly operation over any of the abovementioned business items, the company shall comply with the relevant regulations). Business operation mode: processing and manufacturing, import and export, wholesale and retail services.

The business scope set out above in Article 12 (as proposed to be amended) shall be subject to the items as approved by, and registered with, the Tianjin Municipal Market Supervision and Administration Commission (天津市市场监督管理委员会).

Save for the above amendments, all other provisions of the Articles of Association of the Company shall remain unchanged.

The 2026 2nd Proposed AOA Amendments shall be submitted for shareholders' approval at the 2nd extraordinary general meeting of the Company in 2026 (the "**2026 2nd EGM**") and shall require the approval of shareholders representing not less than two-thirds (2/3) of the voting rights held by the shareholders attending the 2026 2nd EGM, in accordance with the PRC Company Law. A circular to shareholders containing, *inter alia*, further information on the 2026 2nd Proposed AOA Amendments, will be despatched to shareholders in due course.

By order of the Board

Jiao Yan
Secretary to the Board of Directors
4 September 2026